

This press release may not be published, distributed or disseminated, directly or indirectly, in part or in its entirety, to or within the United States, Australia, Canada, Japan or any other country where this would constitute a violation of applicable laws.

Closing and results of the capital increase

NATUREX raises €48.8m

Press Release

Avignon, 21st October 2011

The capital increase launched by NATUREX on 4 October 2011 met with very high take up by shareholders: 95% of the total number of share warrants (*bons de souscription d'actions* or BSA) were exercised representing 1,219,857 new shares or a total amount of €46,354,566. This statement includes shares from the exercise of BSA which have been negotiated and exercised during the exercise period from 5 October until 13 October, especially those of Natraceutical which have been reclassified, as disclosed in the press release dated 13 October.

As announced a placement in shares corresponding to 319,915 non exercised BSA was conducted on 20 October 2011 and closed on the same day in advance.

The new shares were placed by CM-CIC Securities and Berenberg Bank, Joint Lead Managers and Bookrunners, at a price of €50.50 per share resulting accordingly in a unit price for the repurchase of unexercised BSA of €2.5.

As a result, gross proceeds raised by NATUREX amounted to €48,785,920.

The success of this capital increase carried out in a difficult market environment highlights shareholders' interest and confidence in NATUREX and its development project.

The exercise and the listing period for BSA freely allotted on 5 October 2011 was closed on 13 October 2011. After completion of the centralisation process, 95% of the BSA were exercised on the basis of 6,419,200 BSA exercisable after cancellation of 2,540 BSA linked to treasury shares held by the Company on 4 October 2011 and in light of the fact that no stock options were exercised on 12 October 2011.

After shareholders exercised 6,419,200 BSA, the 63,983 new shares issued from the 319,915 BSA unexercised at 13 October 2011 were sold through a placement, after they were repurchased by NATUREX acting as an agent on commission (*commissionnaire*), by the lead managers and bookrunners for the capital increase.

This placement was closed in advance on 20 October 2011. The new shares were sold through a placement at a price of €50.50 per share resulting accordingly in a unit price for the repurchase of unexercised BSA of €2.5.

This repurchase price will be paid to financial intermediaries maintaining accounts for holders of these BSA repurchased on 26 October 2011, the date for settlement-delivery and the listing of new shares resulting from this capital increase. The new shares will be admitted to trading on Euronext of NYSE Euronext Paris as of 26 October 2011 under the same ISIN code as existing shares.

Overall, through this capital increase NATUREX was successful in raising gross proceeds of €48,785,920 through the issue of 1,283,840 new shares.

The success of this capital increase will provide NATUREX with resources to pursue its development program as announced in previous press releases.

After this operation, the capital of NATUREX will consist of 7,705,580 shares representing 6,402,373 voting rights, with the following breakdown:

	Nb of shares	% capital	% Voting rights
NATUREX S.A	2,540		-
SGD	1,205,115	15.64%	18.82%
Jacques DIKANSKY	13,190	0.17%	0.21%
Natraceutical	1,995,002	25.89%	9.49%
Concert	3,213,307	41.70%	28.52%
Thierry LAMBERT	1,024	0.01%	0.02%
Stéphane DUCROUX	4,837	0.06%	0.11%
Directors	5,861	0.07%	0.13%
Free float	4,483,872	58.19%	71.35%
Total shareholders	7,705,580	100%	100%

Notice to the public

A prospectus that was registered with the French financial market authority (*Autorités des Marchés Financiers* or "AMF") under No.11-442 on 3 October 2011 is available free of charge at the registered office of NATUREX, from the lead managers and may be consulted and downloaded at the websites of NATUREX (www.naturex.com and the AMF (www.amf-france.org).

About Naturex

Naturex is the world leader in specialty plant-based ingredients.

The Group, organised around three strategic markets - Food & Beverage, Nutrition & Health and Personal Care -, produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetics industries.

Naturex's head office is based in Avignon. Naturex employs 950 people and has high-performance industrial resources across its 11 industrial sites in Europe (France, Italy, Spain, United Kingdom and Switzerland), in Morocco, the United States, Brazil and Australia. The company draws on its worldwide sales presence through a fully dedicated sales network in 19 countries (France, Italy, Spain, United Kingdom, Belgium, Germany, Switzerland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, United States, Canada, Brazil and Mexico).

Naturex enjoys the highly favourable underlying trend linked to increasing demand for natural-origin products and provides manufacturers with personalised solutions in order to meet the expectations of the end consumers. The Group's strength lies in its positioning on specific products which constitute niche markets, thanks to strong sourcing capacity and sustained Research & Development.

You can receive all of NATUREX's financial information free of charge by signing up on:
www.naturex.com

► Upcoming events

- Actionaria (Paris) 18-19 november 2011

► Next publications

- Q3 2011 sales 04 november 2011
- Q3 2011 results 30 november 2011

Naturex has been listed since October 1996 on NYSE Euronext in Paris, compartment B



Number of shares comprising the capital: 6,410,931

- 6,318,272 ordinary shares (ISIN FR0000054694)
- 1,387,308 preferred shares (ISIN FR0010833251)

Naturex is part of the CAC Small and Gaïa Indexes.

Naturex is eligible for "long only" Deferred Settlement Service (SRD).

MNEMO: NRX - Reuters: NATU.PA - Bloomberg: NRX: FP

► Contacts

Jacques Dikansky

President and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89

naturex@naturex.com

Thierry Lambert

Vice-President

Tel.: +33 (0)4 90 23 96 89

t.lambert@naturex.com

Carole Alexandre

Investor Relations

Tel.: +33 (0)4 90 23 78 28

c.alexandre@naturex.com

Anne Catherine Bonjour

Actus Finance Press Relations

Tel.: +33 (0)1 53 67 36 93

acbonjour@actus.fr